Human interferon-beta inhibits binding of HIV-1 gp41 to lymphocyte and monocyte cells and binds the potential receptor protein P50 for HIV-1 gp41.
Previous findings have indicated that HIV-1 gp41 like human type I interferon (IFN) could inhibit lymphocyte proliferation and up-modulate MHC class I, II and ICAM-1 molecule expression, and a common epitope exists between gp41 and type I interferon (IFN-alpha and -beta) in the receptor binding regions. To clarify the relationship between human type I interferon and HIV-1 gp41, we tried to inhibit recombinant soluble gp41-binding to human T, B and monocyte cell lines by human IFN-alpha, -beta and -gamma. It was interestingly observed that IFN-beta after preincubating with cells could inhibit the binding of rsgp41 to H9, Raji and U937 cells (T, B and monocyte cell lines), while this binding could not be inhibited by another type I interferon (IFN-alpha) and a type II interferon (IFN-gamma). It was further examined whether human IFN-alpha and -beta bind to the gp41 binding protein P50. In ELISA-assay, the human IFN-beta, but not IFN-alpha, could bind to P50 which was identified as a potential cellular receptor protein for gp41-binding. By the affinity capillary electrophoresis (ACE) analysis, formation of stable IFN-beta-P50 complex was observed. These results indicate that IFN-beta binds the potential receptor protein P50. Based on these experimental evidences and previous studies, it was presumed that the potential cellular receptor protein P50 may be the 51 kDa subunit of human IFN-alpha/beta receptor, which needs to be verified in the future.